
Opinion|Videos|July 11, 2024
Limitations on Optimal Biomarker Testing Rates
A panel of experts discuss the current limitations of optimal biomarker testing rates in the community.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What may currently limit optimal biomarker testing rates in the community?
Advertisement
Related to this article

FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, according to a study.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

A TriNetX retrospective cohort found adults with alopecia areata—especially women—face a nearly doubled glaucoma risk, with implications for ophthalmology and comorbidities.

β3 agonists were not linked to lower dementia incidence vs anticholinergics among 830,393 adults treated for overactive bladder, a cohort study found.

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
3
FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5

